Drotrecogin alfa is a recombinant form of activated human protein C which was previously used to treat patients with severe sepsis and organ failure. Drotrecogin alfa was typically given to critically ill patients in whom severe adverse events were common, but it was never linked to an increase in significant serum enzyme elevations during therapy or to instances of clinically apparent liver injury.